Advertisement

Tumor Biology

, Volume 36, Issue 6, pp 4377–4386 | Cite as

Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer

  • Yong Liu
  • Honggen Liu
  • Xuegang Luo
  • Jingyu Deng
  • Yuan Pan
  • Han Liang
Research Article

Abstract

SET and MYND domain-containing protein 3 (SMYD3) plays a key role in the progression of human cancer. Matrix metalloproteinase (MMP)-9 is being related to tumor progression. It has been reported that SMYD3 and MMP-9 are overexpressed in human cancers. However, the exact roles of SMYD3 and MMP-9 in the metastasis and prognosis of gastric cancer (GC) remain unclear. The expressions of SMYD3 and MMP-9 were detected by semiquantitative reverse transcription polymerase chain reaction and Western blotting in gastric cancer and adjacent nontumor tissues. In addition, SMYD3 and MMP-9 expressions were analyzed by immunohistochemistry in formalin-fixed samples from 186 gastric cancer patients. The messenger RNA (mRNA) and protein expression levels of SMYD3 and MMP-9 in gastric cancer tissues were both significantly higher than those in adjacent nontumor tissues. In addition, the expression of SMYD3 was correlated with size of primary tumor and lymph node metastasis, while size of primary tumor and serosal invasion were identified as the independently relative factors of MMP-9 expression in GC tissues. SMYD3 expression and MMP-9 expression in GC tissues were significantly and positively correlated. Multivariate analysis results demonstrated that degree of differentiation, lymph node metastasis, TNM stage, SMYD3 expression, and MMP-9 expression were the independent prognostic indicators of gastric cancer. SMYD3 and MMP-9 may play important roles in tumor invasion, metastasis, and prognosis and could work as promising targets for prognostic prediction in gastric cancer.

Keywords

Stomach Neoplasm SMYD3 MMP-9 Prognosis 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 31470816).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17–20.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 2012;7:340–3.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Luo XG, Xi T, Guo S, Liu ZP, Wang N, Jiang Y, et al. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life. 2009;61:679–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen LB, Xu JY, Yang Z. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J Gastroenterol. 2007;13:5718–24.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Liu Y, Luo X, Deng J, Pan Y, Zhang L, Liang H. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma. Tumour Biol. 2014. doi: 10.1007/s13277-014-2891-z.Google Scholar
  9. 9.
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am. 2001;10:383–92.PubMedGoogle Scholar
  12. 12.
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10:8229–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003;104:504–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, et al. Enhanced radiosensitization and chemosensitization in NF-kappaB suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer. 2004;108:912–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287–97.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chu D, Zhang Z, Li Y, Zheng J, Dong G, Wang W, et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011;129:887–95.CrossRefPubMedGoogle Scholar
  18. 18.
    Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, et al. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012;72:810–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Jaskelioff M, Peterson CL. Chromatin and transcription: histones continue to make their marks. Nat Cell Biol. 2003;5:395–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Luo XG, Ding Y, Zhou QF, Ye L, Wang SZ, Xi T. SET and MYND domain containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells. J Biosci Bioeng. 2007;103:444–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem. 2009;284:19867–77.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett. 2009;280:78–85.CrossRefPubMedGoogle Scholar
  23. 23.
    Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14:3133–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Sampieri CL, de la Peña S, Ochoa-Lara M, Zenteno-Cuevas R, León-Córdoba K. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World J Gastroenterol. 2010;16:1500–5.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res. 2004;10:3110–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Liu Y, Deng J, Luo X, Pan Y, Zhang L, Zhang R, et al. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer. Med Oncol. 2015;32:404. doi: 10.1007/s12032-014-0404-y.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yong Liu
    • 1
  • Honggen Liu
    • 2
  • Xuegang Luo
    • 3
  • Jingyu Deng
    • 1
  • Yuan Pan
    • 1
  • Han Liang
    • 1
  1. 1.Department of Gastric CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and TherapyTianjinChina
  2. 2.Department of OncologyFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjinChina
  3. 3.Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education, College of BiotechnologyTianjin University of Science and TechnologyTianjinChina

Personalised recommendations